These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1360315)

  • 21. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CY 208-243, a novel dopamine D-1 receptor agonist, fails to modify dopamine release in freely moving rats.
    Imperato A; Di Chiara G
    Eur J Pharmacol; 1989 Jan; 160(1):155-8. PubMed ID: 2565816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities.
    Lahti RA; Figur LM; Piercey MF; Ruppel PL; Evans DL
    Mol Pharmacol; 1992 Sep; 42(3):432-8. PubMed ID: 1357542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functions of dopamine in the extrapyramidal and limbic systems. Clues for the mechanism of drug actions.
    Di Chiara G; Morelli M; Acquas E; Carboni E
    Arzneimittelforschung; 1992 Feb; 42(2A):231-7. PubMed ID: 1586394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of gamma-acetylenic GABA, an enzyme-activated irreversible inhibitor of GABA-transaminase, on dopamine pathways of the extrapyramidal and limbic systems.
    Palfreyman MG; Huot S; Lippert B; Schechter PJ
    Eur J Pharmacol; 1978 Aug; 50(4):325-36. PubMed ID: 699960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-Methyl-D-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems.
    Singh NA; Midgley LP; Bush LG; Gibb JW; Hanson GR
    Brain Res; 1991 Aug; 555(2):233-8. PubMed ID: 1681999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [SDZ HDC 912 as a dopamine receptor partial agonist: the effect on spontaneous locomotor activity in mice].
    Kameda H; Watanabe H
    Yakubutsu Seishin Kodo; 1991 Oct; 11(5):327-30. PubMed ID: 1688174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FCE 23884, substrate-dependent interaction with the dopaminergic system. II. Preclinical biochemical studies.
    Carfagna N; Caccia C; Mantegani S; Cavanus S; Fornaretto MG; Buonamici M; Rossi AC; Roncucci R; Fariello RG
    J Pharmacol Exp Ther; 1991 Oct; 259(1):356-64. PubMed ID: 1681088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in the regulation of acetylcholine release upon D2 dopamine and N-methyl-D-aspartate receptor activation between the striatal complex of reptiles and the neostriatum of rats.
    Henselmans JM; Hoogland PV; Stoof JC
    Brain Res; 1991 Dec; 566(1-2):8-12. PubMed ID: 1687666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
    Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC
    Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of (+)-4-propyl-9-hydroxynaphthoxazine on midbrain dopamine neurons: an electrophysiological study.
    Kelland MD; Freeman AS; LeWitt PA; Chiodo LA
    J Pharmacol Exp Ther; 1990 Oct; 255(1):276-84. PubMed ID: 1976800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemispheric asymmetry in behavioral response to D1 and D2 receptor agonists in the nucleus accumbens.
    Belcheva I; Bryer JB; Starkstein SE; Honig M; Moran TH; Robinson RG
    Brain Res; 1990 Nov; 533(2):286-91. PubMed ID: 1981170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymmetric elevation of striatal dopamine D2 receptors in the chakragati mouse: neurobehavioral dysfunction in a transgenic insertional mutant.
    Fitzgerald LW; Miller KJ; Ratty AK; Glick SD; Teitler M; Gross KW
    Brain Res; 1992 May; 580(1-2):18-26. PubMed ID: 1354555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ventral pallidal neuronal responses to dopamine receptor stimulation in the nucleus accumbens.
    Yang CR; Mogenson GJ
    Brain Res; 1989 Jun; 489(2):237-46. PubMed ID: 2568154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P
    Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SDZ 208-911, an amino-ergoline with partial dopamine agonist properties, dose dependently increases cocaine self-administration in the rat.
    Pulvirenti L; Smith D; Koob GF
    Psychopharmacology (Berl); 1994 Jan; 113(3-4):518-20. PubMed ID: 7862868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of acetylcholine release by D1, D2 dopamine receptors in rat striatum under freely moving conditions.
    Ajima A; Yamaguchi T; Kato T
    Brain Res; 1990 Jun; 518(1-2):193-8. PubMed ID: 1975213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.
    Costall B; Domeney AM; Naylor RJ; Tyers MB
    Br J Pharmacol; 1987 Dec; 92(4):881-94. PubMed ID: 2962686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Savoxepine fails to selectively influence glucose metabolism in the rat limbic system.
    Cascella NG; Tarazi FI; Shirakawa O; Tamminga CA
    Psychopharmacology (Berl); 1994 Mar; 114(2):275-80. PubMed ID: 7838920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.